Neuphoria Therapeutics (NEUP) Accounts Payables (2020 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Accounts Payables of $627185.0 for Q1 2026, down 15.85% year-over-year from $745336.0 in Q1 2025, and up 20.45% quarter-over-quarter from $520709.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Accounts Payables (2020 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Accounts Payables for 7 consecutive years, with $627185.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 15.85% year-over-year to $627185.0; the TTM figure through Mar 2026 stood at $627185.0 (down 15.85% YoY), while the FY2025 annual figure was $1.2 million, down 48.55% from the prior year.
- Accounts Payables advanced to $627185.0 in Q1 2026 per NEUP's latest filing, from $520709.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $2.3 million in Q2 2023 and bottomed at $520709.0 in Q4 2025.
- Historically, Accounts Payables has averaged $1.3 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 109.8% — and 2025, when it tumbled 65.98%.
- Neuphoria Therapeutics' Accounts Payables stood at $1.1 million in 2022, then soared by 109.8% to $2.3 million in 2023, then tumbled by 34.58% to $1.5 million in 2024, then sank by 65.98% to $520709.0 in 2025, then grew by 20.45% to $627185.0 in 2026.
- Business Quant data shows NEUP's Accounts Payables at $627185.0 in Q1 2026, $520709.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Neuphoria Therapeutics | 21.28 Mn | 1.84 Mn | - | 627,185.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 627,185.00 |
| Dec 31, 2025 | 520,709.00 |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.15 Mn |
| Mar 31, 2025 | 745,336.00 |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 2.24 Mn |
| Jun 30, 2023 | 2.34 Mn |
| Jun 30, 2022 | 1.12 Mn |
| Jun 30, 2021 | 792,189.61 |
| Jun 30, 2020 | 1.52 Mn |